EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY-NC-ND 4.0

The PERFORMANCE II Trial

William A Gray, D Christopher Metzger, James Zidar, Sasko Kedev, Ivo Petrov, Peter Soukas, Elad Levy, William Bachinsky, J Michael Bacharach, Piero Montorsi, Victor Novack, Alexandra Lansky und 1 weitere

JACC: Cardiovascular Interventions · 2025-02 · 18 (3) · 367-376

DOI: 10.1016/j.jcin.2024.10.031 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-02. Verfasst von William A Gray und 12 weiteren Autor:innen. Beteiligte Einrichtung: Lankenau Heart Institute and the Division of Cardiology, Main Line Health, Wynnewood, Pennsylvania, USA. Electronic address: grayw@mlhs.org. Hauptthemen laut MEDLINE: Stents, Embolic Protection Devices, Carotid Stenosis, Angioplasty, Balloon. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Several randomized clinical trials have shown that the composite endpoint of death, stroke, and myocardial infarction (MI) is equivalent between carotid artery stenting and carotid endarterectomy. However, the risk of minor stroke has been consistently higher with carotid artery stenting. OBJECTIVES: The authors sought to evaluate the safety and effectiveness of a novel carotid stent system comprised of a stent, an adjustable integrated embolic filter and a postdilation balloon, in patients at elevated risk for adverse events from carotid endarterectomy. METHODS: PERFORMANCE II (Protection against Emboli during caRotid artery stenting using a 3-in-1 delivery system comprised oF a pOst-dilation balloon, integRated eMbolic filter, and A Novel Carotid stEnt II) was a prospective, multicenter, single-arm study. The primary endpoint was the composite of major adverse events defined as death, all stroke, and MI within 30 days of the procedure, plus ipsilateral stroke through 12 months. RESULTS: A total of 305 patients were enrolled at 32 centers in the United States and Europe. The mean age was 69.6 ± 7.5 years; 65.9% were male, and 20% were symptomatic. The mean lesion length was 19.1 ± 6.7 mm, and 34.5% of lesions were severely calcified. At 30 days, there were 4 minor strokes (1.3%), with no major strokes. There was 1 cardiac death on day 30, resulting in a stroke/death rate of 1.6% and a stroke/death/MI rate of 2.3%. The 12-month primary endpoint occurred in 2.8%; there were no major strokes, clinically driven target lesion revascularizations, stent thromboses, or neurological deaths. The 30-day all stroke plus ipsilateral stroke through 12 months rate was 1.8%. CONCLUSIONS: The rate of major adverse events was extremely low, demonstrating the study system is a safe, effective, and durable treatment option for high-risk patients. (Protection against Emboli during caRotid artery stenting using a 3-in-1 delivery system comprised oF a pOst-dilation balloon, integRated eMbolic filter, and A Novel Carotid stEnt II [PERFORMANCE II]; NCT04201132).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StentsEmbolic Protection DevicesCarotid StenosisAngioplasty, BalloonHumansMaleFemaleAgedProspective StudiesTreatment OutcomeTime FactorsRisk FactorsProsthesis DesignStrokeMyocardial InfarctionMiddle AgedUnited StatesEurope

Stichwörter der Autor:innen

carotid artery stentingcerebral embolic protectionperiprocedural stroke

Autor:innen und Institutionen

  • Lankenau Heart Institute and the Division of Cardiology, Main Line Health, Wynnewood, Pennsylvania, USA. Electronic address: grayw@mlhs.org.
  • Ballad CVA Heart and Vascular Institute, Kingsport, Tennessee, USA.
  • UNC-Rex Healthcare, Raleigh, North Carolina, USA.
  • University Clinic of Cardiology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia.
  • Cardiology and Angiology Department, Acibadem City Clinic Cardiovascular Center, Sofia, Bulgaria.
  • Brown University Health Cardiovascular Institute, The Miriam Hospital, Providence, Rhode Island, USA.

Zitieren

APA

Gray, W. A., Metzger, D. C., Zidar, J., Kedev, S., Petrov, I., Soukas, P., Levy, E., Bachinsky, W., Bacharach, J. M., Montorsi, P., Novack, V., Lansky, A., & Langhoff, R. (2025). The PERFORMANCE II Trial. JACC: Cardiovascular Interventions, 18(3), 367-376. https://doi.org/10.1016/j.jcin.2024.10.031

Vancouver

Gray WA, Metzger DC, Zidar J, Kedev S, Petrov I, Soukas P, et al. The PERFORMANCE II Trial. JACC: Cardiovascular Interventions. 2025;18(3):367-376. doi:10.1016/j.jcin.2024.10.031

BibTeX
@article{Gray2025,
  author = {Gray, William A and Metzger, D Christopher and Zidar, James and Kedev, Sasko and Petrov, Ivo and Soukas, Peter and Levy, Elad and Bachinsky, William and Bacharach, J Michael and Montorsi, Piero and Novack, Victor and Lansky, Alexandra and Langhoff, Ralf},
  title = {The PERFORMANCE II Trial},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {3},
  pages = {367--376},
  doi = {10.1016/j.jcin.2024.10.031}
}
Kostenlos starten →